首页> 外文期刊>Journal of endovascular therapy: an official journal of the International Society of Endovascular Specialists >Cardiva Catalyst II vascular access management device in percutaneous diagnostic and interventional procedures with same-day discharge (Catalyst II trial).
【24h】

Cardiva Catalyst II vascular access management device in percutaneous diagnostic and interventional procedures with same-day discharge (Catalyst II trial).

机译:当天出院的经皮诊断和介入程序中的Cardiva Catalyst II血管通路管理设备(Catalyst II试验)。

获取原文
获取原文并翻译 | 示例
       

摘要

PURPOSE: To present a prospective, single-center trial of the Cardiva Catalyst II, a vascular closure device that provides temporary hemostasis after the procedure and is removed under manual compression, leaving no material behind. METHODS: During a 16-month period between April 2008 and July 2009, 400 procedures (100 interventions, 300 diagnostic procedures) were performed on 351 nonconsecutive patients (185 men; mean age 60.2 +/- 12.0 years, range 27-93). All interventions were performed utilizing bivalirudin for anti-thrombin therapy. Initial follow-up was done at a mean 1.3 +/- 0.7 days after the index procedure in all patients. Final follow-up, for diagnostic procedures as well as interventions, was performed at a mean 15.4 +/- 7.1 days. The primary and secondary endpoints were the rate of major and minor vascular complications, respectively. RESULTS: Successful deployment of the device was reported in 397 (99.3%) procedures, which were primarily in retrograde fashion (97.0%) from the right groin (92.5%). In most cases (309, 77.2%), a 5-F sheath was used. A major vascular complication occurred after 1 intervention; none was noted after diagnostic procedures. Minor vascular complications were recorded after 2 interventions and 5 diagnostic procedures. Overall vascular complication rates were 0.25% for major sequelae and 1.75% for minor events. Mean time to discharge after diagnostic procedures was 145.0 +/- 21.2 minutes versus 295.1 +/- 44.1 minutes after interventional procedures (p < 0.05). There was no death, stroke, myocardial infarction, or urgent hospital transfer in the study cohort. CONCLUSION: Cardiva Catalyst is safe and effective device in achieving local hemostasis after percutaneous diagnostic procedures and interventions performed under bivalirudin anticoagulation. The use of this device with an appropriate protocol facilitates same-day discharge.
机译:目的:提供Cardiva Catalyst II的一项前瞻性,单中心试验,Cardiva Catalyst II是一种血管闭合装置,可在手术后提供暂时止血,并在手动加压下将其移除,不留任何物质。方法:在2008年4月至2009年7月的16个月内,对351例非连续患者(185例男性,平均年龄60.2 +/- 12.0岁,范围27-93)进行了400例检查(100例干预,300例诊断)。所有干预均使用比伐卢定进行抗凝血酶治疗。在所有患者中,平均随访时间为指标手术后平均1.3 +/- 0.7天。对诊断程序和干预措施的最终随访平均为15.4 +/- 7.1天。主要终点和次要终点分别是主要和次要血管并发症的发生率。结果:397(99.3%)例报告了该设备的成功部署,其中主要是从右腹股沟(92.5%)逆行(97.0%)。在大多数情况下(309,77.2%),使用了5-F护套。 1次干预后发生了严重的血管并发症;诊断程序后未发现任何异常。在进行了2次干预和5次诊断后,记录了轻微的血管并发症。重大后遗症的总血管并发症发生率为0.25%,次要事件为1.75%。诊断程序后的平均出院时间为145.0 +/- 21.2分钟,而介入程序后为295.1 +/- 44.1分钟(p <0.05)。在研究队列中没有死亡,中风,心肌梗塞或紧急医院转移。结论:在经比伐卢定抗凝治疗和经皮比鲁鲁定抗凝治疗后,Cardiva Catalyst是一种安全有效的装置,可实现局部止血。将此设备与适当的协议配合使用有助于当天放电。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号